Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Exact Sciences Corporation

New activity is brewing for Exact Sciences ( ($EXAS) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vot...

Exact Sciences Sets February 20, 2026 Virtual Meeting for Shareholder Vote on $105-per-Share Abbott Merger

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Crinetics Pharmaceuticals (CRNX – Research Report)...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	EXAS	$102.50	+0.16%	1.02M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	EXAS	$102.50	+0.2%	1.02M
3
4
5
6

EXAS

EXAS

Dividend Overview

Get Exact Sciences Corporation Data in Excel

Get Exact Sciences Corporation Data in Excel